Moreover, reduced Mfn2 levels are also detected in mouse models of steatosis or NASH, and its re-expression in a NASH mouse model ameliorates the disease progression [143–145]. This evidence concerns the gene MFN2 and metabolic dysfunction-associated steatohepatitis.